Trials / Enrolling By Invitation
Enrolling By InvitationNCT07180511
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
A Multicenter, Randomized, Parallel, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Moderate to Severe Atopic Dermatitis.
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (estimated)
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 10mg QY201 Placebo tablet | 10mg QY201 Placebo tablet |
| DRUG | 20mg QY201 Placebo tablet | 20mg QY201 Placebo tablet |
| DRUG | 10mg QY201 tablet | 10mg QY201 tablet |
| DRUG | 20mg QY201 tablet | 20mg QY201 tablet |
Timeline
- Start date
- 2025-03-12
- Primary completion
- 2027-05-18
- Completion
- 2027-07-19
- First posted
- 2025-09-18
- Last updated
- 2025-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07180511. Inclusion in this directory is not an endorsement.